Pembrolizumab: a new PD-1 inhibitor as first-line therapy for non-small cell lung cancerZHANG Jing-ru, ZHAO Li-bo, GU Jian969-972
Budget impact analysis of icotinib for terminal non-small cell lung cancerLUO Xue-yan, YUAN Quan, YAO Wen-bing973-977
Binary drug protection in China and reformation on Chinese pharmaceutical patent linkage systemDOU Xia-rui, WU Rang-feng978-983
A review on formulation and preparation of dry powder inhaler drug productsGAO Lei, MA Yu-nan, WANG Ya-min, NING Li-li, YAO Fang-yao984-987
Advances in the strategies to enhance oral drug absorption for achlorhydric patientsFU Zhong-hua, LIU Mei, WANG Xiao-ke, FAN Yun-zhou, WANG Ai-feng, GAO Chun-sheng988-993
The improvement of testing standards about related substances of piperacillin sodium and sulbactam sodium for injectionGAO Liang, ZHANG Yu-ying, SUN Ming-jie, WANG Ting994-999
Drug polymorphic transformation during manufacturing process of solid dosage formsGAO Jing, TENG Zai-jin, SHU Jian-hui, JIANG Shu-guang1000-1005
A tolerance trial of extract of rhizoma gastrodiae in Chinese healthy subjectsLI Rui, ZHAO Ying-pan, GAO Hong-yang, WANG Shu-ge, LI Bo, ZI Ming-jie, HOU Jin-ru, ZHAO Yang, LI Qing-na, CAO Wei-yi, GAO Rui1006-1011
A multi-center clinical evaluation trial of Fufang Qinlan Oral Liquid in the treatment of cold (acute upper respiratory tract infection) with external invaded wind heat syndromeSHI Cun-zhong, ZHEN Hui, LIU Xin-qiao1012-1018
Sample sizes of reference-scaled average bioequivalence for highly variable drugs: implementation of FDA approachYU Yong-pei, YAN Xiao-yan, YAO Chen, XIA Jie-lai1019-1024